REACH - Non-regulatory announcement*

Fusion Antibodies plc

("Fusion" or the "Company")

Investor presentations

Results update

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that management will host two investor presentations in September and October 2025.

London investor event

The London investor event will take place on Wednesday, 17 September 2025 at 2.30pm. To register to attend this event, please use the link below or email [email protected].

I would like to attend the Fusion Antibodies London presentation.

Proactive Investors event

The Company will also present at the Proactive One2One Investor Forum on Thursday, 9 October 2025 at The Chesterfield Mayfair, 35 Charles Street, London, W1J 5EB. The event will start at 6.00pm. You can register to attend this event here.

The Company also intends to hold another investor event in Belfast city centre in September 2025, further details of which will be announced in due course. To register your interest to attend this event, please send an email using this link. 

The Company will be publishing its results for the year ended 31 March 2025 in the first half of September 2025 and further details will be provided in due course.

Enquiries: 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

*About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.